Publication | Open Access

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

OncologyNeoadjuvant TherapyCheckmate 141Cancer ManagementClinical TrialsSingle-agent TherapyHead And Neck CancerCancer TreatmentNeck OncologyHealth-related Quality-of-life ResultsMedicineRadiation OncologyCancer ResearchHealth Sciences